Analysis

Tg Therapeutics, Inc. (TGTX) Stock Analysis

Tg Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to TGTX.

websiteTGTX/analysis/TGTX

Tg Therapeutics, Inc.

Tg Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to TGTX.

Stock profile

Ticker

TGTX

Asset type

Stock

Market cap

$8.15B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Tg Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • TGTX primary listing
  • NKB2
  • A1JXW7
  • 1TGTX
  • 0VGI

Latest Tg Therapeutics, Inc. news

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Pot...

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized ...

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data ...

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ETNEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. ...

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing...

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MR...

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infu...

Research sections

Valuation

Review valuation context for Tg Therapeutics, Inc..

Future growth

Review future growth context for Tg Therapeutics, Inc..

Past performance

Review past performance context for Tg Therapeutics, Inc..

Financial health

Review financial health context for Tg Therapeutics, Inc..

Dividend

Review dividend context for Tg Therapeutics, Inc..

Management

Review management context for Tg Therapeutics, Inc..

Ownership

Review ownership context for Tg Therapeutics, Inc..

Other information

Review other information context for Tg Therapeutics, Inc..

Community

Review community context for Tg Therapeutics, Inc..